Matinas BioPharma Holdings Inc - Asset Resilience Ratio
Matinas BioPharma Holdings Inc (MTNB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MTNB current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Matinas BioPharma Holdings Inc's Asset Resilience Ratio has changed over time. See Matinas BioPharma Holdings Inc (MTNB) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Matinas BioPharma Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MTNB company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Matinas BioPharma Holdings Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Matinas BioPharma Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Matinas BioPharma Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Allakos Inc
NASDAQ:ALLK |
Biotechnology | 52.08% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT |
Biotechnology | 41.14% |
|
Youcare Pharmaceutical Group Co. Ltd. A
SHG:688658 |
Biotechnology | 10.25% |
|
MoonLake Immunotherapeutics
NASDAQ:MLTX |
Biotechnology | 14.01% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Matinas BioPharma Holdings Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Matinas BioPharma Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $12.64 Million | -- |
| 2023-12-31 | 35.73% | $8.97 Million | $25.10 Million | +7.92pp |
| 2022-12-31 | 27.81% | $21.93 Million | $78.87 Million | -18.81pp |
| 2021-12-31 | 46.62% | $28.59 Million | $61.33 Million | -18.54pp |
| 2020-12-31 | 65.17% | $46.25 Million | $70.97 Million | +51.24pp |
| 2019-12-31 | 13.93% | $5.61 Million | $40.24 Million | +12.85pp |
| 2017-12-31 | 1.07% | $155.00K | $14.42 Million | -0.51pp |
| 2016-12-31 | 1.59% | $156.00K | $9.82 Million | +0.40pp |
| 2015-12-31 | 1.19% | $100.00K | $8.41 Million | -1.79pp |
| 2014-12-31 | 2.97% | $100.00K | $3.36 Million | -- |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more